Equities

Hikma Pharmaceuticals PLC

HIK:LSE

Hikma Pharmaceuticals PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,909.00
  • Today's Change-4.00 / -0.21%
  • Shares traded14.96k
  • 1 Year change3.69%
  • Beta0.4204
Data delayed at least 20 minutes, as of Apr 29 2024 09:04 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 25-Apr-24
Select bar for recommendation details.
Recommendations25-Apr-24
Buy4
Outperform2
Hold6
Underperform0
Sell0

Share price forecast

The 10 analysts offering 12 month price targets for Hikma Pharmaceuticals Plc have a median target of 2,361.71, with a high estimate of 5,209.37 and a low estimate of 2,003.85. The median estimate represents a 23.46% increase from the last price of 1,913.00.
High172.3%5,209.37
Med23.5%2,361.71
Low4.7%2,003.85

Dividends

In 2023, Hikma Pharmaceuticals PLC reported a dividend of 0.73 USD, which represents a 30.11% increase over last year. The 11 analysts covering the company expect dividends of 0.71 USD for the upcoming fiscal year, a decrease of 2.60%.
Div growth (TTM)30.11%
More ▼

Earnings history & estimates

Hikma Pharmaceuticals Plc reported annual 2023 earnings of 2.21 per share on Feb 22, 2024.
Average growth rate+10.73%
More ▼

Revenue history & estimates

Hikma Pharmaceuticals PLC had revenues for the full year 2023 of 2.88bn. This was 14.22% above the prior year's results.
Average growth rate+6.99%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.